One-year outcome with a bovine pericardial valve

Figures

• 

  The Cingular bovine pericardial valves, including aortic and mitral bioprosthesis. Left panel, lateral view. Middle panel, outflow view. Right panel, inflow view.

• 

  Figure 1. The Cingular bovine pericardial valves (Shanghai Cingular Biotech Corporation, Shanghai, China), including aortic and mitral bioprosthesis. Left panel, Lateral view. Middle panel, Outflow view. Right panel, Inflow view.

• 

  Figure 2. Study flow of patients through the clinical trial of Cingular bovine pericardial valves (Shanghai Cingular Biotech Corporation, Shanghai, China).

• 

  Figure 3. Kaplan-Meier curves for survival after the Cingular bovine pericardial valve (Shanghai Cingular Biotech Corporation, Shanghai, China) implantations according to different surgical types. AVR, Aortic valve replacement; MVR, mitral valve replacement; DVR, double valve (aortic and mitral valve) replacement; CI, confidence interval; NA, not applicable.

• 

  Figure 4. Improvement of New York Heart Association functional class in patients receiving Cingular bovine pericardial valve (Shanghai Cingular Biotech Corporation, Shanghai, China) implantations during 1-year follow-up compared with preoperative status.

• 

  Video 1. Dr Chen introduces the background, method, outcomes, and conclusion of this clinical trial. Video available at: https://www.jtcvs.org/article/S2666-2736(20)30023-1/fulltext.

• 

  Figure 5. A prospective, multicenter, single-arm trial for Cingular bovine pericardial valves (Shanghai Cingular Biotech Corporation, Shanghai, China). This study found that the Cingular bovine pericardial valve was safe and effective for surgical aortic or mitral valve replacement. Early hemodynamic performance was excellent even for the small sizes of aortic bioprostheses. CI, Confidence interval; PPM, patient-prosthesis mismatch; AVR, aortic valve replacement.